<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457561</url>
  </required_header>
  <id_info>
    <org_study_id>19710808</org_study_id>
    <nct_id>NCT00457561</nct_id>
  </id_info>
  <brief_title>Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamamatsu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamamatsu University</source>
  <brief_summary>
    <textblock>
      Decreased body fat mass, possibly mediated through the effects of elevated serum adiponectin&#xD;
      levels, may be associated with requirements for higher recombinant human erythropoietin doses&#xD;
      and a subsequent worse prognosis in patients beginning hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <condition>Hemodialysis</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who started hemodialysis therapy from August 2000 to May 2001 in 11 dialysis&#xD;
             centers in the Shizuoka prefecture area, and who survived for more than 3 months after&#xD;
             the start of hemodialysis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nothing particular.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Naro Ohashi, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Department of Medicine, Hamamatsu University School of Medicine</affiliation>
  </overall_official>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 5, 2007</study_first_submitted>
  <study_first_submitted_qc>April 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2007</study_first_posted>
  <last_update_submitted>April 5, 2007</last_update_submitted>
  <last_update_submitted_qc>April 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2007</last_update_posted>
  <keyword>The relationship between all-cause mortality in patients introduced hemodialysis and recombinant human erythropoietin dose and serum adiponectin level</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

